

Publishing Partners

New names for a new year



Schiller is one of the world's leading companies in the development, production, and distribution of medical devices for cardiopulmonary diagnostics, patient monitoring, and emergency medicine.

Founded in 1974, the company has become known for its computerised ECG with automatic measurement and interpretation, defibrillators, as well as patient monitoring devices that are used all over the world and even in space (ISS). Distinguished by financial autonomy, and regular growth and innovations, the company employs over 700 employees and oversees an extensive distributional network worldwide.

Most products are developed and manufactured at the headquarters facility in Baar (Switzerland) and in Wissembourg (Schiller Médical S.A.S., France). The product range comprises various ECG systems for human and veterinary medicine. 'Tailor-made' measuring systems include high-performance and very compact portable devices, such as the CARDIOVIT AT-1, as well as integrated networking solutions, such as the multi-functional CARDIOVIT CS-200 ergo-spirometry system. Fast and precise diagnoses are also ensured by Schiller's combined systems, which comprise ECG, Holter ECG, spirometry and/or blood pressure recorder in one device. For emergency medicine and patient monitoring Schiller offers pocket-size defibrillators (FRED easyport) for high-risk patients, as well as multifunctional systems such as DEFIGARD 5000 and ARGUS PRO LifeCare2 for rescue services and hospitals.

The Art of Diagnostics is boundless, infinitely creative and inspires the company to continuously improve its products. However size is not as important to Schiller as is strength and the dedication to create long-term value for customers, patients, and employees.



The Medicines for Malaria Venture (MMV) is recognised as the leading product development partnership (PDP) in the field of antimalarial drug research and development. It was established as a foundation in 1999, and registered in Switzerland. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing, and facilitating delivery of new, effective, and affordable antimalarial drugs. The Foundation's vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate the disease.

MMV's strength comes from its product development partnership model reflected in its network of more than

170 pharmaceutical, academic and endemic-country partners in over 40 countries. MMV also works in close partnership with a number of WHO programmes that include TDR, the Global Malaria Programme (GMP) and Roll Back Malaria (RBM).

With more than 65 promising projects, MMV is currently managing the largest <http://www.mmv.org/research-development/science-portfolio> portfolio of antimalarial R&D projects ever assembled. In February 2012, one MMV-supported artemisinin combination therapy (ACT), received a positive scientific opinion from the European Medicines Agency (EMA). In October 2011, dihydroartemisinin-piperazine an ACT developed in partnership with sigma-tau, was granted regulatory approval by the EMA and in November 2010, Guilin's artesunate injection for the treatment of severe malaria was approved by the WHO's Prequalification programme with assistance from MMV. In addition, a child-friendly version of the ACT Coartem®, was developed by Novartis in partnership with MMV and launched in 2009. Since February 2012, more than 100 million courses of treatment have been supplied to 39 malaria-endemic countries.



Crown Agents

The Crown Agents is a leading international development firm that works with leaders across the world to make profound changes to systems, organisations, and society. They provide professional and financial services to public sector and international organisations across the world, particularly focusing on health systems strengthening, fund and grant management, public financial management (especially revenue, debt and expenditure management), and public sector transformation. Crown Agents have an extensive global footprint, with permanent offices in more than 20 countries and ongoing projects in over 100 countries. They work on the basis of long-term partnerships with our clients: national governments, non-governmental service providers, international agencies, and donors.

Crown Agents health work focuses on improving access to healthcare by building sustainable institutions, organisations, systems, and human capacity. Their projects help to secure a healthy future for the world's most vulnerable people by:

- Building reliable health supply chain systems and capacity
- Designing health system governance arrangements
- Improving financial management of health system funds
- Developing human resource management strategies for the health sector
- Combining physical improvements with strategic leadership and multi-stakeholder coordination.